pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 34 Non-oncology: 17
Oncology: 17
Under Consideration for Negotiation 34 Non-oncology: 16
Oncology: 18
Completed Negotiations 554 With Letter of Intent: 479
Without agreement: 75
Negotiations That Were Not Pursued 95

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Retevmo Eli Lilly Canada Inc. indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients
Retevmo Eli Lilly Canada Inc. For the treatment of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
Retevmo Eli Lilly Canada Inc. monotherapy treatment of rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma (DTC) in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment wi

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Emgality Eli Lilly Canada Inc. Prevention of migraine
Kirsty BGP Pharma ULC, d.b.a. Viatris Canada Diabetes Mellitus, Type 1 & 2
pdp-Amlodipine Pendopharm, a division of Pharmascience Inc. Treatment of mild to moderate essential hypertension and management of chronic stable angina
Tecartus Gilead Sciences Canada Inc. For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)
Semglee BGP Pharma ULC, d.b.a. Viatris Canada Diabetes Mellitus, Type 1 & 2
Vitrakvi Bayer Inc. For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in seve

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Spinraza Biogen Canada Inc. spinal muscular atrophy (SMA) in patients aged 18 years or older
Minjuvi Incyte Biosciences Canada Corporation in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell t